Warren Buffett is satisfied with his IBM holdings, but is Jim Cramer satisfied with the stock? Not exactly. ‘Warren Buffett is addicted to buybacks and dividends. I want more than that. They have to make acquisitions,’ said Cramer, portfolio manager of TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money’. Cramer suggested that IBM buy ClickSoftware Technologies (CKSW) and CyberArk (CYBR). Cramer made the comments while answering viewers’ questions from social media from the floor of the New York Stock Exchange Tuesday. Cramer also discussed a number of healthcare and biotechnology stocks, saying that investors should buy Allergan (AGN), Biogen (BIB), Gilead (GILD). Cramer also said he prefers Allegan over Valeant (VRX) and said he’s staying away from Amicus Therapeutics (FOLD) and almost all of the small biotech companies, which he said are under year-end selling pressure. Send your questions to Jim Cramer on his Facebook page or on Twitter @jimcramer, using #CramerQ.
More from Video
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.